8-K
filed September 29, 2023, 7:59 PM ET
ticker VTGN
CIK 0001411685
other material
confidence high
sentiment neutral
materiality 0.15
Vistagen stockholders re-elect directors, approve equity plan increase to 1M shares
Vistagen Therapeutics, Inc.
- Seven director nominees re-elected; votes for ranged from 1.44M to 1.67M, withholds 416k to 642k.
- Advisory say-on-pay approved with 1.38M for, 607k against, 96k abstain.
- Amendment to 2019 Omnibus Equity Incentive Plan approved: authorized shares increased from 600k to 1M.
- Ratification of WithumSmith+Brown as auditors for FY ending March 31, 2024 approved (3.93M for).
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Vistagen Therapeutics, Inc. shareholders approved Election of Directors at the 2023-09-25 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-09-25
Exact text from the filing
Proposal No. 1 – Election of Directors For Withheld Ann M. Cunningham, MBA 1,443,789 641,810
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Vistagen Therapeutics, Inc. shareholders approved Advisory Vote to Approve Executive Compensation (Say-on-Pay Proposal) at the 2023-09-25 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2023-09-25
Exact text from the filing
Proposal No. 2 – Advisory Vote to Approve Executive Compensation (Say-on-Pay Proposal) For Against Abstain Votes 1,382,535 607,263 95,801
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Vistagen Therapeutics, Inc. shareholders approved Ratification of Appointment of Auditors at the 2023-09-25 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-09-25
Exact text from the filing
Proposal No. 4 – Ratification of Appointment of Auditors For Against Abstain Votes 3,933,402 334,951 42,733
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Vistagen Therapeutics, Inc. shareholders approved Amendment to the Vistagen Therapeutics, Inc. Amended and Restated 2019 Omnibus Equity Incentive Plan at the 2023-09-25 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2023-09-25
Exact text from the filing
Proposal No. 3 – Amendment to the Vistagen Therapeutics, Inc. Amended and Restated 2019 Omnibus Equity Incentive Plan For Against Abstain Votes 1,389,517 667,326 28,756
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.